Clincosm LogoSign in Get a demo

donafenib

Showing 1 - 4 of 4
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

A Single Center Real-world Study of Donafenib in Treatment of

Recruiting
  • Donafenib
  • Hepatocellular Carcinoma
    • Shanghai, Shanghai, China
      Zhongshan Hospital, Fudan University,
    Mar 17, 2022

    Donafenib Combined With TACE-based Treatment in Unresectable HCC

    Recruiting
    • Hepatocellular Carcinoma
    • Donafenib
    • Donafenib combined with TACE
    • Shanghai, China
      Fudan University
    Mar 21, 2022

    Donafenib Trial in Shanghai (Donafenib, PD-1, TACE)

    Recruiting
    • Donafenib
    • Donafenib, PD-1
    • TACE
    • Shanghai, Shanghai, China
      Zhongshan Hospital, Fudan University,
    Mar 4, 2022

    Carcinoma, Carcinoma, Hepatocellular, Liver Tumors Trial in Guangzhou (Hepatic arterial infusion chemo, Folfox Protocol,

    Not yet recruiting
    • Carcinoma
    • +8 more
    • Hepatic arterial infusion chemotherapy
    • +2 more
    • Guangzhou, Guangdong, China
      Lei Zhang
    Sep 22, 2021